The appeal centers on a decision from the District Court for the District of Delaware concerning the validity of a patent claim under the doctrine of obviousness-type double patenting (ODP). The court affirms the lower court's ruling, finding that claim 5 of one patent cannot be used as an ODP reference to invalidate claim 26 of another, citing a recent controlling decision in a similar case. The opinion was decided on June 9, 2025, and is noted as nonprecedential. Read the full case summary here: https://www.cafcnewsbriefs.com/post/acadia-pharmaceuticals-inc-v-aurobindo-pharma-ltd-decided-june-9-2025